文章摘要

血清甲基化SFRP2 在上消化道肿瘤诊断中的可行性

作者: 1王真真, 2,3赵国栋, 1陈莹, 1,4马萍, 1,4顾兵, 1,4李洪春
1 徐州医科大学医学技术学院，江苏 徐州 221004
2 浙江大学昆山创新中心，浙江大学昆山生物检测实验室，江苏 昆山 215300
3 苏州唯善生物科技有限公司，江苏 苏州 215300
4 徐州医科大学附属医院检验科，江苏 徐州 221004
通讯: 李洪春 Email: 13775891123@163.com
DOI: 10.3978/j.issn.2095-6959.2019.05.004
基金: 国家自然科学基金 (81702103)；江苏省自然科学基金 (BK20170252)；江苏省高校自然科学研究项目(16KJD320005)；江苏省青年医学人才 (QNRC2016780)；徐州市科技计划项目 (KC16SY157)。

摘要

目的：探究结直肠癌(colorectal cancer，CRC)癌甲基化分泌卷曲相关蛋白2(secreted f r izzled-related protein 2，SFRP2)在上消化道肿瘤诊断中的可行性。方法：收集41例上消化道肿瘤患者和36例无相关胃肠疾病患者的血清，采用基于甲基化特异性PCR的方法检测甲基化的SFRP2(mSFRP2)。结果：SFRP2的灵敏度在上消化道癌中为68.3%，在食管癌中为60.0%，在胃癌中为71.0%。特异性为77.8%，提示SFRP2的甲基化状态与患者年龄、性别及肿瘤属性(原发性或继发性)之间不存在相关性(P>0.05)。此外，随着肿瘤大小和病理分化程度的增加，SFRP2甲基化阳性率也逐渐增加。结论：CRC甲基化标志物SFRP2用于上消化道肿瘤的筛查是可行的，尤其在胃癌检测方面。SFRP2的甲基化检测将是一个新的很有前景的非侵入性的上消化道肿瘤筛查工具。
关键词： 上消化道肿瘤；甲基化标志物；SFRP2基因

Feasibility of methylated SFRP2 in serum for diagnosis of upper gastrointestinal tract cancers

Authors: 1WANG Zhenzhen, 2,3ZHAO Guodong, 1CHEN Ying, 1,4MA Ping, 1,4GU Bing, 1,4LI Hongchun
1 School of Medical Technology, Xuzhou Medical University, Xuzhou Jiangsu 221004, China
2 Zhejiang University Kunshan Innovation Institute, Zhejiang University Kunshan Biotechnology Laboratory, Kunshan Jiangsu 215300, China
3 Suzhou VersaBio Technologies Inc., Suzhou Jiangsu 215300, China
4 Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou Jiangsu 221004, China

CorrespondingAuthor: LI Hongchun Email: 13775891123@163.com

DOI: 10.3978/j.issn.2095-6959.2019.05.004

Foundation: This work was supported by the National Natural Science Foundation (81702103), Jiangsu Provincial Natural Science Foundation (BK20170252)

Abstract

Objective: To explore the feasibility of serum methylation SFRP2 in the diagnosis of upper gastrointestinal tract cancers (UGITC). Methods: The serum of 41 patients with UGITC and 36 patients without gastrointestinal tract diseases individuals were collected and tested by methylation specific PCR based assay detecting methylated biomarkers—methylated SFRP2 (mSFRP2). Results: The sensitivities of SFRP2 were 68.3% in UGITC, 60.0% in esophageal carcinoma and 71.0% in gastric carcinoma. The specificity was 77.8%. There was no evidence proving the correlation between methylation status of SFRP2 and patients’ age, gender and tumor attribute (primary or secondary) (P>0.05). In addition, methylation positive rates were increasing gradually with the increasing of tumor size and clinical differentiation. Conclusion: It is possible to use colorectal cancer methylated biomarkers (SFRP2) to detect upper gastrointestinal tract cancers. Methylated SFRP2 in serum may have a new promising prospect as the non-invasive screening tool for UGITC.
Keywords： upper gastrointestinal tract cancers; methylated biomarker; SFRP2 gene

文章选项

下载引文

分享